000132944 001__ 132944
000132944 005__ 20240229105041.0
000132944 0247_ $$2doi$$a10.1007/s11940-018-0498-1
000132944 0247_ $$2pmid$$apmid:29594595
000132944 0247_ $$2ISSN$$a1092-8480
000132944 0247_ $$2ISSN$$a1534-3138
000132944 0247_ $$2altmetric$$aaltmetric:35023365
000132944 037__ $$aDKFZ-2018-00583
000132944 041__ $$aeng
000132944 082__ $$a610
000132944 1001_ $$0P:(DE-He78)5ef8651b0f857b9c640aa5b1498c43b5$$aPlatten, Michael$$b0$$eFirst author$$udkfz
000132944 245__ $$aVaccine Strategies in Gliomas.
000132944 260__ $$aPhiladelphia, Pa.$$bCurrent Science Inc.$$c2018
000132944 3367_ $$2DRIVER$$aarticle
000132944 3367_ $$2DataCite$$aOutput Types/Journal article
000132944 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1660118080_9237$$xReview Article
000132944 3367_ $$2BibTeX$$aARTICLE
000132944 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000132944 3367_ $$00$$2EndNote$$aJournal Article
000132944 520__ $$aTo discuss the current state of glioma vaccine development and highlight the challenges associated with clinical implementation of these approaches.Vaccination strategies against gliomas have matured considerably during the past years, although proof-of efficacy from controlled clinical trials is still lacking. Advances in antigen discovery, including the definition of neoepitopes including epidermal growth factor receptor variant III (EGFRvIII), isocitrate dehydrogenase (IDH)1R132H and Histone (H)3.3K27M, using multi-omic approaches and computational algorithms allow targeting single antigens, but also implementing truly personalized approaches. In addition, new concepts of vaccine manufacturing including RNA and DNA vaccines improve immunogenicity and applicability in personalized settings. As an increasing amount of clinical data defy the concept of the central nervous system (CNS) as a strictly immunoprivileged site, novel vaccine approaches enter the clinic including critical efforts to identify biomarkers of response and resistance and strategies to overcome the immunosuppressive glioma microenvironment.
000132944 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000132944 588__ $$aDataset connected to CrossRef, PubMed,
000132944 7001_ $$0P:(DE-He78)e579130c57e8c686ed1c2dedfa595985$$aBunse, Lukas$$b1$$udkfz
000132944 7001_ $$0P:(DE-He78)567e98aaf50a1f3be9ef2f365dda213d$$aRiehl, Dennis$$b2$$udkfz
000132944 7001_ $$0P:(DE-He78)e681100c540b628a2bdbd48772b4fb50$$aBunse, Theresa$$b3$$udkfz
000132944 7001_ $$0P:(DE-He78)0f9fbf5fd70dad2bba0760cee65c9613$$aOchs, Katharina$$b4$$udkfz
000132944 7001_ $$0P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee$$aWick, Wolfgang$$b5$$eLast author$$udkfz
000132944 773__ $$0PERI:(DE-600)2076603-8$$a10.1007/s11940-018-0498-1$$gVol. 20, no. 5, p. 11$$n5$$p11$$tCurrent treatment options in neurology$$v20$$x1534-3138$$y2018
000132944 909CO $$ooai:inrepo02.dkfz.de:132944$$pVDB
000132944 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5ef8651b0f857b9c640aa5b1498c43b5$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000132944 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e579130c57e8c686ed1c2dedfa595985$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000132944 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)567e98aaf50a1f3be9ef2f365dda213d$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000132944 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e681100c540b628a2bdbd48772b4fb50$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000132944 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0f9fbf5fd70dad2bba0760cee65c9613$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000132944 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000132944 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000132944 9141_ $$y2018
000132944 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000132944 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000132944 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCURR TREAT OPTION NE : 2015
000132944 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000132944 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000132944 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000132944 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000132944 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000132944 9201_ $$0I:(DE-He78)G160-20160331$$kG160$$lNeuroimmunologie und Hirntumorimmunologie$$x0
000132944 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x1
000132944 9201_ $$0I:(DE-He78)G808-20160331$$kG808$$lG808 IMT IM Platform$$x2
000132944 9201_ $$0I:(DE-He78)G370-20160331$$kG370$$lKKE Neuroonkologie$$x3
000132944 980__ $$ajournal
000132944 980__ $$aVDB
000132944 980__ $$aI:(DE-He78)G160-20160331
000132944 980__ $$aI:(DE-He78)L101-20160331
000132944 980__ $$aI:(DE-He78)G808-20160331
000132944 980__ $$aI:(DE-He78)G370-20160331
000132944 980__ $$aUNRESTRICTED